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and clinical results in 26 cases
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This report describes the methodology, diagnostic yield, and adverse events (AE) asso-
ciated with frame-based stereotactic brain biopsies (FBSB) obtained from 26 dogs with
solitary forebrain lesions. Medical records were reviewed from dogs that underwent FBSB
using two stereotactic headframes designed for use in small animals and compatible
with computed tomographic (CT) and magnetic resonance (MR) imaging. Stereotac-
tic plans were generated from MR and CT images using commercial software, and
FBSB performed both with (14/26) and without intraoperative image guidance. Records
were reviewed for diagnostic yield, defined as the proportion of biopsies producing a
specific neuropathological diagnosis, AE associated with FBSB, and risk factors for
the development of AE. Postprocedural AE were evaluated in 19/26 dogs that did
not proceed to a therapeutic intervention immediately following biopsy. Biopsy targets
included intra-axial telencephalic masses (24/26), one intra-axial diencephalic mass, and
one extra-axial parasellar mass. The median target volume was 1.99 cm3. No differences
in patient, lesion, or outcome variables were observed between the two headframe
systems used or between FBSB performed with or without intraoperative CT guidance.
The diagnostic yield of FBSB was 94.6%. Needle placement error was a significant risk
factor associated with procurement of non-diagnostic biopsy specimens. Gliomas were
diagnosed in 24/26 dogs, and meningioma and granulomatous meningoencephalitis in
1 dog each. AE directly related to FBSB were observed in a total of 7/26 (27%) of dogs.
Biopsy-associated clinical morbidity, manifesting as seizures and transient neurological
deterioration, occurred in 3/19 (16%) of dogs. The case fatality rate was 5.2% (1/19 dogs),
with death attributable to intracranial hemorrhage. FBSB using the described apparatus
was relatively safe and effective at providing neuropathological diagnoses in dogs with
focal forebrain lesions.
Keywords: brain tumor, dog, glioma, neurooncology, neurosurgery
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Introduction
Over a century ago, Horsley and Clarke first described the use of a
device andmethod for stereotactic intracranial surgery in animals
(1). Since then, the field of stereotactic neurosurgery has been
evolving nearly continuously and in parallel with advancements
in neuroimaging technology. This has resulted in the development
of numerous stereotactic devices and techniques for use in human
diagnostic and therapeutic intracranial interventions, but brain
biopsy remains one of themost commonly performed stereotactic
neurosurgical procedures (2).
Stereotactic apparatus designed for clinical use were origi-
nally frame based, in which the patient is immobilized in a
rigid headframe. The external headframe provides a stereotactic
coordinate system and allows registration and correspondence
of this system to the three-dimensional map of the brain gen-
erated by computed tomographic (CT) or magnetic resonance
(MR) images obtained from the patient while in the headframe.
Frame-based stereotactic brain biopsy (FBSB) procedures have
been utilized routinely for a variety of indications in humans
for nearly 50 years, and most reports indicate that FBSB is safe
and effective, with procedural morbidity ranging between 0
and 13%, accuracy to within 2mm, and diagnostic yields typi-
cally exceeding 90% (2–4). In contemporary human neurosurgi-
cal practice, frameless image-guided neuronavigational (FLIGN)
biopsy techniques have been gaining popularity at many insti-
tutions, as FLIGN is the most technologically advanced, min-
imally invasive, and flexible technique currently available for
brain biopsy. However, reports indicate that FLIGN and FBSB
have similar accuracies, diagnostic yields, and overall types and
rates of complications when performed by experienced neurosur-
geons (5, 6).
Numerous brain biopsy techniques have also been described
in dogs. These include open and minimally invasive free-
hand, several FBSB techniques capable of being performed with
and without image guidance using both permanent and dis-
posable frame systems, and FLIGN procedures (7–21). Many
of these investigations have focused on the description and
validation of individual devices and techniques in normal
canines or canine cadavers (11–13, 15–17, 19–21). Collec-
tively, these studies demonstrate that there are multiple feasi-
ble biopsy methods capable of accurately targeting brain lesions
within the range of error generally considered acceptable for
clinical use in veterinary patients. However, there exist few
published reports, which include a total of 98 dogs, whose
specific objectives included the descriptions of the technique,
clinical utility of, and complications associated with brain
biopsy in cohorts of dogs with spontaneous intracranial disease
(8–10, 14, 17).
The purpose of this study was to describe a technique for
FBSB in a population of dogs with spontaneous forebrain mass
lesions using two stereotactic headframe systems, and to report
the clinical results of FBSB including diagnostic yield, intraoper-
ative adverse events (AE), post-operative AE, and potential risk
factors associated with the development of AE or non-diagnostic
biopsy specimens in dogs undergoing FBSB.
Materials and Methods
All procedures performed in this study were approved by the Vir-
ginia Tech orWake Forest University institutional animal care and
use committees under various protocols (08-048-VT, A09-143-
WFU, 11-132-VT, 12-014-VT, or 14-235-VT) depending upon
which therapeutic trial the dog was enrolled in, and at which
institution the treatment was administered.
Medical Record Review
Themedical record from each dogwas reviewed and the following
data recorded: signalment (breed, age, sex, bodyweight); historical
clinical signs and neurological examination findings at admission;
modified canineKarnofsky performance score (KPS) at admission
(22); lesion laterality (side) and anatomic location within the
brain; lesion volume as determined below; date the FBSB was
performed; FBSB performed with intraoperative image guidance
(yes/no); duration of the FBSB procedure, as determined from the
time of initial patient arrival into the CT suite for the planning
scan until completion of closure of the surgical wound; final
histopathological diagnosis and, where applicable, tumor grade;
number of brain biopsies attempted and number obtained; and
the number of non-diagnostic biopsies in each patient.
As all of the patients included in this study were enrolled in
clinical trials, AE reports associated with the FBSB procedure
were available in patient medical records. AE were recorded,
classified, and graded according to the Cancer Therapy Evaluation
Program’s CTCAE-Common Terminology Criteria for Adverse
Events (23). Postprocedural AE were evaluated in only those dogs
that did not proceed to a therapeutic intervention immediately
following biopsy.
Stereotactic Apparatus
MRI Interventions Dynatech Headframe
This is a commercially available, MR-compatible, dedicated small
animal headframe (Dynatech Machining, Union City, CA, USA)
that has been used previously for stereotactic intracranial pro-
cedures in dogs (24). The frame is manufactured from plex-
iglass, aluminum, brass, and nylon components (Figure 1A),
and is compatible with stereotactic manipulator arms outfitted
for an 18.70mm square rostrocaudal (R/C or A/P) bar. In this
study, a single stereotactic micromanipulator arm was used with
both headframes (1760-SB, Kopf Instruments, Tujunga, CA, USA;
Figure 1A) and for both the phantom scans using needle blanks
and actual FBSB procedures. Thismanipulator attaches to the R/C
bar of the frames and can be adapted to accommodate numer-
ous instruments, including biopsy needles. The baseplate of the
manipulator is capable of calibrated movements in two planes,
and can thus be used to direct instruments in oblique trajectories.
The riser (vertical) and lateral arms of the manipulator contained
scaled adjustment guides, which according to the manufacturer,
allows placement of instruments within 0.1mm of the desired
target location. Biopsy needle guide tubes can be readily attached
to the manipulator arm using a knurled thumb screw assembly
that couples the guide tube seat to the peripheral aspect of the
lateral arms of the micromanipulator (Figure 1C).
Frontiers in Veterinary Science | www.frontiersin.org July 2015 | Volume 2 | Article 202
Rossmeisl et al. Stereotactic brain biopsy in dogs
FIGURE 1 | Stereotactic instrumentation used for biopsy of
canine brain masses. (A) MRI Interventions Dynatech headframe with
attached micromanipulator arm and canine patient in the headframe
(inset). (B) Virginia Tech Custom headframe, with surface rendered
three-dimensional reconstructed CT image of canine patient in the
frame (inset). (C) Micromanipulator with biopsy needle and guide tube
assembly mounted to the lateral arm using a knurled thumb screw
coupler (inset).
Virginia Tech Custom Headframe
The apparatus was designed by the investigators using commercial
design software (Solidworks 2012, Dassault Systems, Waltham,
MA, USA) and manufactured on-site (Machine Shop, College of
Engineering, Virginia Tech, Blacksburg, VA, USA). Design modi-
fications allowed for CT and MR compatibility of the device, and
accommodation of a larger range of skull sizes and conformations
by incorporating lateral (x-axis) adjustability into the rostrocau-
dal bar (R/C; z-axis) center line distance, dorsoventral (y-axis)
adjustability through the use of a telescoping frame pedestal with a
45 cm working length, and 18.70mm square R/C bars that accept
ear bar block mounts at 10mm increments along the length of the
R/C bar from R/C bar 0 to 50mm (Figure 1B). The R/C bar
was calibrated100mm from 0. CT andMRI compatibility of the
final prototype used in the study was attained by manufacturing
the frame pedestal, ear bar mounts, and base plate from polyether
ether ketone (PEEK, Curbell Plastics, Orchard Park, NY, USA),
and R/C bars and ear bars of the frame of polyoxymethylene
acetal resin (Delrin POM, DuPont, Wilmington, DE, USA). The
bite plate, bite plate tongue stop screw, and x-plane bars were
machined from aluminum sheet, bar, and rod (6AL-4V ELI,
OnlineMetals, Seattle, WA, USA) stock. Stop screws and washers
for use in securing the R/C bars and telescoping pedestal in fixed
positions were machined from threaded and smooth Nylon 6–6
rod stock, respectively (United States Plastics Corp., Lima, OH,
USA). Incremental, 1mm, Vernier scales were laser-etched into
theR/Cbars, earbars, and bite plate tongue adapter (GSI Lumonics
Excimer, Bedford, MA, USA) to allow for patient and stereotactic
coordinate registration to the frame (25).
Pre-Operative Diagnostics, Imaging, and Lesion
Volume Quantification
All dogs had a diagnostic MR scan of the brain performed within
3weeks of the biopsy procedure. These MR scans were obtained
on a variety of low- and high-field (0.2–3.0 T) magnets from
several referring veterinary academic and private practices using
non-standardized sequences and image acquisition parameters.
All pre-operative MR data sets contained pre-contrast T1- and
T2-weighted images in at least two planes, at least a single pla-
nar FLAIR sequence, and post-contrast T1-weighted images in
at least two planes. All dogs also had a complete blood count,
serum biochemical profile, prothrombin time, and activated par-
tial thromboplastin time performed within 24 h of the FBSB
procedure.
The volume of each mass lesion was determined using image
analysis software (OsiriXMD, OsiriX Imaging Software, Osirix
Foundation, Geneva, Switzerland). Volumes were defined from
transverse T2-weighted MR images, as not all lesions demon-
strated contrast enhancement (Figure 2). Manually defined
regions of interest (ROIs) were generated for individual contigu-
ousMR image slices, and volumes calculated with OsiriXMDROI
volume software, which accounts for interslice gaps.
Stereotactic Imaging and Planning
Dogs were anesthetized with a total intravenous protocol con-
sisting of premedication with a variety of benzodiazepines and
fentanyl, induction with propofol, and anesthetic maintenance
with propofol and fentanyl or remifentanil intravenous constant
rate infusions. All dogs received cefazolin (22mg/kg IV q 90min)
for the duration of the FBSB procedure. Following induction of
general anesthesia, the dog was placed in sternal recumbency
upon a rigid plexiglass backboard. The head of each dog was
then affixed to the headframe using a vinylpolysiloxane putty
(Express STD, 3M ESPE Dental Products, St. Paul, MN, USA)
dental impression of themaxillary arcade that wasmolded into the
biteplate. Three-point immobilization of the head occurred using
the bite plate, ear bars, and memory foam and cloth pads placed
ventral to the mandible, and full-patient immobilization further
achieved by bolting the headframe baseplate to the plexiglass
backboard using threaded nylon 6–6 bolts and nuts (MRD frame;
United States Plastics Corp., Lima, OH, USA) placed through
predrilled holes in the backboard or plastic C-clamps [Virginia
Tech custom headframe (VTC) frame, Cavision Enterprises, Van-
couver, BC, Canada]. Pre- and post-contrast (iohexol; 0.45ml/kg,
IV) CT scans were then obtained with a 16-slice scanner (Aquil-
ion, Toshiba, Japan) using the following standardized technique:
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FIGURE 2 | Frame-based stereotactic biopsy planning procedure from a
dog with a Grade II astrocytoma. Diagnostic, transverse post-contrast
T1-weighted (A) and T2-weighted (B) images demonstrating intra-axial,
non-enhancing mass lesion in the right piriform lobe. The patient is anesthetized,
immobilized in the headframe, and CT images obtained for stereotactic planning
(C–F), imported into image analysis software (C–F) and co-registered with the
prior diagnostic MR (G). The planned trajectory is then simulated and verified
using a needle blank (H) and the final stereotactic coordinates recorded.
1mm slice thickness, with no gap, and edge enhancement algo-
rithm with dogs in the fully instrumented headframe in sternal
recumbency (12). Various image sizes and fields of viewwere used,
depending on the size of the dog as well as the particular study the
patient was enrolled in.
DICOM formatted images of the stereotactic CT and diag-
nostic MR were imported into image analysis software packages
(OsiriXMD andMimics v.14.1,Materialise, Leuven, Belgium), co-
registered, and the stereotactic coordinates and trajectories for
lesion biopsy determined by a single investigator (John Henry
Rossmeisl; Figure 2). The rostrocaudal coordinates were deter-
mined based on linear (ear bar) reference markers. Mediolateral
and dorsoventral coordinates and/or angular trajectories were
measured directly from DICOM images using osseous anatomic
landmarks, including the external sagittal crest and external sur-
face of the skull. Generally, the needle entry point and biopsy
trajectory were planned to traverse the shortest distance of normal
brain between the skull and the target, and avoid sulci, major
vasculature, and ventricular structures. However, in some cases
in which catheter- or electrode-based therapeutic interventions
were to be performed following biopsy, the biopsy trajectory
deviated from these criteria such that both the diagnostic biopsy
and therapeutic procedure could be performed through a single
craniectomy defect (26, 27). After the trajectory was planned, the
manipulator arm was attached to the headframe and the biopsy
trajectory simulated using a 20-gauge needle blank (QuinckeNee-
dle, BD Medical, Franklin Lakes, NJ, USA) that was positioned at
the desired needle entry point into the calvarium. The CT scan
was then repeated to include the headframe and attached needle
phantom using contiguous 1mm slices using the identical field of
view and magnification factors as the initial scan for each patient
(Figure 2H). The target depth was measured from the external
surface of the craniectomy defect to the measured position of
the mid-portion of the side-cutting port of the needle within the
lesion. The final stereotactic (x, y, and z) coordinates obtained
from the phantom scan were stored in the planning software and
registered to the headframe.
Stereotactic Biopsy Procedure
Following stereotactic planning, the head of each dog was clipped
and aseptically prepared for surgery. Dogs were transported to the
operating theater while being maintained under anesthesia and
immobilized in the headframe. The stereotactic coordinates were
transferred from the planning station into the operating room,
and then re-registered onto the frame and verified. In each dog, a
routine unilateral rostrotentorial approach to the skull ipsilateral
to the location of the mass was performed. Following comple-
tion of the rostrotentorial approach, a perforated drape (Apuzzo,
Integra LifeSciences, Plainsboro, NJ, USA) was applied over the
standard surgical drapes. The perforated drape assists mounting
of the sterile manipulator arm to the non-sterile headframe. The
manipulator arm and guide tube assembly was then mounted to
the frame, the final stereotactic coordinates verified and recorded,
and the manipulator arm rotated out of the field to allow creation
of a 3- to 5-mm diameter burr-hole craniectomy defect using
a high-speed pneumatic drill. The exposed dura was cauterized
using bipolar cautery, and then the dura perforated with a 20-
gauge needle. After creation of the burr-hole and dural defects,
the biopsy needle was advanced down the guide tube to confirm
that no impediments to the intended trajectory were encountered.
A single investigator (John Henry Rossmeisl) performed all
biopsy procedures using 16-gaugeNashold side-cutting aspiration
biopsy needles with a 10mm cutting channel (Integra Radionics,
Burlington, MA, USA; Figure 3). The biopsy needle has a Luer
lock coupler to which a syringe can be attached in order to apply
slight negative pressure. When the inner cannula of the biopsy
needle is rotated 180°, the side-cutting port opens. The depth
to target was verified and a depth stop applied to the proximal
portion of the biopsy needle.
A saline-filled syringe was attached to the needle, and the
assembly flushed, and the side-cutting port closed. The needle
was passed through the guide tube and gradually advanced to
the planned depth using the manipulator arm controls. Once at
the predetermined depth, the side-cutting port was opened by
rotating the inner hub 180°, and slight negative pressure applied
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by withdrawing on the saline-filled syringe to pull tissue into
the needle. The side-cutting port was then closed and the needle
withdrawn.
The specimen was retrieved in a similar manner, by opening
the port and flushing saline through to eject the specimen into
a sterile cryomold cassette (Figure 4A). Multiple specimens were
typically collected by rotating the biopsy needle aperture in differ-
ent directions, or alternatively by varying the target depth slightly.
For instances in which the target depth was varied, one biopsy was
planned that traversed the junction between normal and diseased
brain tissue. Bone wax was used to occlude the burr-hole defects
prior to closure. Some burr-hole defects were converted into
larger craniectomy defects to accommodate implantation of guide
pedestals that could accommodate passage of diagnostic-intent
FIGURE 3 | Nashold needle with Luer lock proximal end (A) and 10mm
side-cutting channel with depth stop (A,B) used for canine brain
biopsy procedures.
biopsy needles, as well as therapeutic-intent electrodes or infu-
sion cannulae, depending on which clinical protocol the dog was
enrolled in.
For dogs inwhich an intraoperativeCT-guided FBSBprocedure
was performed, following creation of the burr-hole craniectomy
defect in the operating theater, the surgical field was lavaged,
covered with an impregnable, adhesive iodinated barrier drape
and the patient transported under anesthesia to the CT suite
while immobilized in the headframe. After positioning the patient
on the CT couch, additional sterile draping was applied to the
patient and CT unit, in a manner similar as described above.
The manipulator arm was attached to the headframe, set to the
prerecorded coordinates, and the biopsy needle positioned imme-
diately external to the burr-hole defect, and an additional CT
scan performed using the same image acquisition parameters for
each patient as performed for the previously performed phantom
needle scan. The biopsy trajectory was verified by co-registering
the planning phantom CT with the actual biopsy CT, and then
the needle advanced into the target region using the manipulator
arm, and needle placement confirmed with an additional series
of 1mm contiguous CT slices through the region of the mass
lesion (Figure 5), and the biopsy harvested as described above.
The therapeutic protocol that each individual dog was enrolled
in was the determinant of whether or not the procedure was
performed with or without intraoperative image guidance. Fol-
lowing completion of CT-guided FBSB procedures, patients were
then transported back to the operating theater, where the surgical
wound was lavaged copiously and closed routinely. In all dogs, a
final CT scan was performed after wound closure to evaluate for
biopsy-related hemorrhage.
In those dogs in which intraoperative CT-guided FBSB was
performed, the needle placement accuracy was quantified using
a previously described Pythagorean technique (8). Briefly, the
stereotactic coordinates of the needle tip in three planeswere com-
pared to the proposed coordinates recorded from the planning
scan and the error determined using the following formula:
Error = p (Δx)2 + (Δy)2 + (Δz)2
where Δx, Δy, and Δz represent the distances from the actual
needle tip to the planned target site in each of the three
references axes.
FIGURE 4 | Representative pathological features of canine stereotactic
brain biopsies. (A) Intraoperatively, biopsy core specimens are retrieved by
flushing into a cryomold cassette. (B) Subgross photomicrograph of biopsy
from a dog with a grade IV astrocytoma (H&E stain). (C) Cytologic smear
preparation of an oligodendroglioma (Giemsa stain). Neoplastic cells appear to
windrow within the pink proteinaceous background, and are mostly round to
ovoid. Cells contain eccentrically or centrally located, round, ovoid, or
reniform-shaped nuclei with stippled to coarsely stippled chromatin and a single
to sometimes two small to medium-sized nucleoli. There are abundant bare
nuclei. Cytoplasm is small to moderate in volume and basophilic and granular
with distinct cytoplasmic borders; cytoplasm occasionally contains few to rarely
moderate numbers of punctate vacuoles.
Frontiers in Veterinary Science | www.frontiersin.org July 2015 | Volume 2 | Article 205
Rossmeisl et al. Stereotactic brain biopsy in dogs
FIGURE 5 | CT-guided stereotactic biopsy procedure in a dog with
a Grade III oligodendroglioma. Transverse, pre-contrast (A,B) and
post-contrast (C,D) T1-weighted MR (A,D) with corresponding
stereotactic CT planning images (B,E). Intraoperative transverse CT
image (C) with biopsy needle in situ. The craniectomy defect in this
patient has been enlarged to accommodate placement of an implanted
guide pedestal that will later be used to introduce electrodes into the
tumor for therapy. Co-registered CT and MR image (F) demonstrating
needle placement that includes contrast enhancing lesion and the
surrounding brain.
All dogs received buprenorphine (0.03mg/kg, IV or SC, q
6–8 h) for at least 36 h following recovery from the procedure.
For the purposes of this study, diagnostic yield was defined as
the proportion of biopsies producing a specific neuropathological
diagnosis, and was calculated by dividing the number of biopsies
producing diagnoses, by the total number of biopsies submitted. A
failed FBSB procedure was defined as an individual case in which
none of the biopsies obtained yielded a specific neuropathological
diagnosis, or those cases in which brain tissue was unable to be
obtained from the intended target (28).
Processing of Biopsy Specimens
Biopsy specimens were fixed for 24 h in 10% neutral buffered
formalin then paraffin embedded, and 5μm thick sections were
routinely stained with hematoxylin and eosin (H&E; Figure 4B)
and murine monoclonal antibody against glial fibrillary acidic
protein (M0761, clone 6F2, 1:150 dilution; Dako, Carpinteria, CA,
USA). Biopsies were reviewed by at least two board-certified vet-
erinary pathologists, including the pathologist that originally gen-
erated the pathology report included in the medical record, and
for the purposes of this study, another pathologist blinded to the
original diagnosis. In the event of diagnostic discordance between
pathologists, a third blinded pathologist reviewed the biopsy,
with the final diagnosis representing the majority opinion among
the three pathologists. All neoplastic lesions were classified and
graded according to World Health Organization criteria (29). In
select cases in which multiple biopsies were obtained, one biopsy
specimen was sharply divided perpendicular to the axis of the
needle trajectory immediately after harvesting and submitted for
ancillary cell culture, immunohistochemistry, immunoblotting,
cytogenetic, or intraoperative cytologic examinations [Ref. (30);
Figure 4C].
Statistical Analyses
Normal probability plots showed that age, body weight, KPS,
lesion volume, number of biopsies attempted, number of biopsies
obtained, target depth, mean needle error, and procedure dura-
tion were skewed. Subsequently, all continuous variables were
summarized as medians (range). Categorical variables includ-
ing frame type, breed, sex, lesion side, lesion location, diagno-
sis, tumor grade, non-diagnostic biopsies, image-guided biopsies,
and presence of AE were summarized using contingency tables.
Associations between frame type and perioperative characteristics
were tested using a chi-square (number of procedures), Wilcoxon
rank sum test (age, body weight, KPS, lesion volume, number of
biopsies attempted, number of biopsies obtained, mean needle
error, and target depth) and Fisher’s exact test (sex, lesion side,
lesion location, diagnosis, tumor grade, image-guided biopsy,
non-diagnostic biopsies, and AE). Associations between devel-
opment of AE and selected perioperative characteristics were
tested using Wilcoxon rank sum test (dog sequence as function
of surgeon experience, KPS lesion volume, number of biopsies
attempted, needle error, and procedural time) and Fisher’s exact
test (lesion side, lesion location, tumor grade, and production of a
non-diagnostic biopsy). Associations between producing a non-
diagnostic biopsy and perioperative characteristics were tested
using Wilcoxon rank sum test (dog sequence as surgeon expe-
rience, lesion volume, needle error, and procedural time) and
Fisher’s exact test (lesion side, lesion location, and tumor grade).
Regression analysis was used to test the association between
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TABLE 1 | Signalments, headframe type, and lesion characteristics of dogs undergoing stereotactic brain biopsy.
Dog No. Breed Age
(years)
Sex Body
weight (kg)
Frame
type
Lesion side/
location
Diagnosis/
WHO grade
1 Mixed 12 FS 11 VTCa L-Parieto-occipital Mixed glioma-III
2 Boston Terrier 8 MN 12 VTCa R-Temporal-piriform Oligodendroglioma-III
3 Boxer 7 FS 24 MRD L-Piriform Astrocytoma-III
4 Labrador Ret 9 MN 35 VTCa R-Fronto-olfactory Astrocytoma-IV
5 Boxer 9 MN 31 MRD L-Piriform Astrocytoma-II
6 Min Schnauzer 8 FS 7 VTCa R-Fronto-parietal Astrocytoma-III
7 Boston Terrier 10 MN 10 MRD L-Piriform Oligodendroglioma-II
8 Golden Ret 12 FS 29 MRD R-Temporal-piriform Astrocytoma-II
9 Am Staff Terrier 12 MN 36 VTCa R-Fronto-parietal Astrocytoma-IV
10 Boston Terrier 10 FS 11 VTCa R-Piriform Astrocytoma-II
11 Boston Terrier 11 MN 9 VTCa L-Frontal Oligodendroglioma-II
12 French Bulldog 6 FS 8 MRD L-Parieto-occipital GME
13 Bull Terrier 8 MN 32 MRD R-Hemispheric Astrocytoma-III
14 Beagle 9 FS 12 MRDa R-Temporal Astrocytoma-IV
15 Mixed 8 MN 14 MRDa L-Fronto-olfactory Astrocytoma-II
16 Am Staff Terrier 7 FS 26 MRDa L-Thalamic Astrocytoma-III
17 Labrador Ret 6 MN 31 VTC L-Fronto-parietal Astrocytoma- III/IV
18 Mixed 9 MN 7 MRD R-Parieto-occipital Oligodendroglioma-III
19 Boston Terrier 8 MN 14 MRDa L-Frontal Oligodendroglioma-II
20 Mixed 8 FS 20 MRDa L-Temporal Astrocytoma- IV
21 Mixed 7 M 17 VTCa R-Fronto-olfactory Oligodendroglioma-II
22 English Bulldog 8 FS 21 MRDa L-Frontal Astrocytoma-II
23 Boston Terrier 11 MN 10 VTC R-Temporal Astrocytoma-IV
24 Boxer 12 FS 26 VTC R-Parasellar Meningioma-I
25 Boxer 8 FS 37 MRD R-Temporal-piriform Oligodendroglioma-III
26 Mixed 5 MN 27 MRD R-Fronto-parietal Astrocytoma- IV
aBiopsy performed with intraoperative CT-guidance.
GME, granulomatous meningoencephalitis; FS, female spayed; L, left; M, male; MN, male neutered; MRD, MRI Instruments Dynatech headframe; R, right; VTC, Virginia Tech Custom
headframe.
target depth and needle error and between surgeon experience
and procedural time. Association between procedural time and
image-guided versus non-guided procedures was tested using
the Wilcoxon rank sum test. Statistical significance was set to
α= 0.05. All analyses were performed using commercial statis-
tical software (SAS version 9.4, Cary, NC, USA).
Results
Patient Characteristics and Clinical Signs
The study population consisted of 26 consecutive dogs that under-
went FBSB (Table 1). All dogs had clinical signs of forebrain
disease. Signs were focal in 19/26 dogs and multifocal or diffuse
in 7/26. Seizures were the most common clinical sign, being
observed in 22/26 cases. Interictal neurological deficits consistent
with the anatomic location of the tumor were present in 20/22
of the dogs with seizures. Brachycephalic breeds (Boston terriers,
Boxers, English Bulldog) comprised 12/26 cases. The median age
of dogs was 8 years (range, 5–12 years) and the median body
weight was 18.5 kg (range, 7–37 kg). There were 13 neutered
males, 1 intact male, and 12 spayed females. The median admis-
sion KPS was 70 (range, 30–90). All dogs with structural epilepsy
were receiving oral anticonvulsant medications at the time
of admission, including phenobarbital (n= 16), levetiracetam
(n= 7), zonisamide (n= 5), gabapentin (n= 1), and potassium
bromide (n= 1), or various combinations of these medications
(n= 9). All dogs in the study were also receiving oral prednisone
therapy (median 0.85mg/kg/day, range 0.33–1.4mg/kg/day) at
the time of admission. Coagulation profiles were normal in all
26 dogs. Platelet counts were within reference ranges in 24/26
dogs. In 2/26 dogs, platelet clumping prevented accurate count-
ing, but in both of these cases platelet counts were estimated at
150,000/μl.
MR Lesion Features and FBSB Techniques
All dogs had solitary forebrain lesions identified on pre-operative
MR examinations. Fourteen lesions were located in the right fore-
brain, and 12 in the left forebrain (Table 1). Lesions were classified
as intra-axial in 25/26 dogs, and extra-axial in the remaining
dog. Nineteen lesions were described as well marginated, and
the remaining seven poorly demarcated from the surrounding
neuropil. Some degree of contrast enhancement was observed in
20/26 lesions, although the patterns and intensities of contrast
enhancement were highly variable. Themedian lesion volumewas
1.99 cm3 (range, 0.55–6.48 cm3). FBSB was performed with the
VTC headframe in 11 cases, and with the MRD headframe in
15 cases. CT-guided FBSB procedures were performed in 14/26
dogs, and the 12 remaining biopsies were completed without
intraoperative image guidance (Table 1). There were no sig-
nificant differences between surgeon experience (dog order in
which FBSB procedure was performed), patient age, sex, body-
weight, KPS, lesion laterality, lesion location, lesion volume, num-
ber of biopsies attempted, number of biopsies obtained, num-
ber of non-diagnostic biopsies, overall rate of AE, final diag-
nosis, tumor grade, number of procedures, number of image-
guided procedures, or duration of the biopsy procedure for FBSB
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TABLE 2 | Summary of continuous patient, lesion, and biopsy variables by headframe type.
Frame total No.
dogs (CT-guided
biopsies)
Age
(years)
Body
weight (kg)
Admission
KPS
Lesion
volume (cm3)
Biopsies
attempted
Biopsies
obtained
Needle
error (mm)
Target
depth (mm)
MRD n= 15 (6) 10 (5–12) 20 (7–35) 70 (40–80) 2.22 (0.55–6.48) 2 (1–4) 2 (1–4) 1.55 (1.1–3.4) 26 (14–44)
VTC n= 11 (8) 8 (6–12) 12 (10–37) 70 (30–90) 1.27 (0.69–4.98) 2 (1–3) 2 (1–3) 1.50 (0.9–2.0) 21 (15–66)
p Value 0.11 0.94 0.77 0.14 0.12 0.06 0.84 0.35
All data presented as medians and ranges.
KPS, Karnofsky performance score.
TABLE 3 | Analysis of continuous risk factors associated with obtaining a
non-diagnostic stereotactic brain biopsy.
Risk factor Non-diagnostic
biopsies
Diagnostic
biopsies
p Value
N Median
(range)
N Median
(range)
Surgeon experience
(procedure number)
3 10.0 (2.0–20.0) 23 14.0 (1.0–26.0) 0.53
Lesion volume (cm3) 3 1.0 (0.9–1.4) 23 2.2 (0.6–6.5) 0.12
Needle error (mm) 2 2.9 (2.3–3.4) 12 1.5 (0.9–2.1) 0.05*
Procedural duration
(min)
3 118 (86–191) 23 140 (84–149) 0.87
*Statistically significant (p 0.05).
performedwith the VTC or theMRDheadframe (Tables 1 and 2).
The duration of CT-guided FBSB procedures (median 138min,
range 117–191min) was significantly longer than FBSB proce-
dures performed without intraoperative image guidance (median
100min, range 84–118min; p< 0.001). There were no significant
associations observed between surgeon experience and procedu-
ral time (slope= 0.74; 95% CI= 2.35 to 0.88; t(24)= 0.94;
Y = 134.36–0.74(X); r2= 0.04; p= 0.36), or needle error with tar-
get depth (slope= 0.01; 95% CI= 0.03–0.02; t(12)= 0.76;
Y = 1.94 – 0.01(X); r2= 0.05; p= 0.46).
Biopsy Characteristics
In the 26 dogs, a total of 58 biopsies were attempted and 56
biopsy samples obtained and submitted for histopathological anal-
ysis. The median number of biopsies attempted per dog was 2
(range, 1–4), and no individual dog experienced a failed FBSB
procedure. Twenty-five FBSB procedures were performed using
a single needle trajectory. Neuroepithelial neoplasms accounted
for 24/26 diagnoses, including astrocytomas in 16/26 dogs, oligo-
dendrogliomas in 7/26 dogs, and a mixed glioma in 1 dog.
A meningioma was diagnosed in the dog with the extra-axial
mass lesion, and granulomatous meningoencephalitis was diag-
nosed in one dog (Table 1). The overall diagnostic yield was
94.6%, with 53/56 individual biopsies producing specific neu-
ropathological diagnoses. Necrosis, hemorrhage, and astrogliosis,
(n= 1), extensive necrosis precluding cytoarchitectural evalua-
tion (n= 1), and inclusion of only normal brain tissue in the
sample (n= 1) accounted for the three non-diagnostic biopsies.
Among the variables examined for associations with the risk of
obtaining a non-diagnostic biopsy, only needle error was signifi-
cant (Tables 3 and 4).
Adverse Events
Overall, AE attributable to the FBSB procedure were observed
in 7/26 (27%) of dogs. Seven dogs proceeded immediately to
invasive neurosurgical interventions following FBSB, including
one dog that experienced an FBSB-associated intraoperative
AE. Thus, data from 19/26 dogs were included in assessment of
FBSB-related post-operative AE. Intraoperative AEwere observed
in 4/7 dogs, and post-operative AE in 3/7. The case fatality rate
for dogs undergoing FBSB was 5.2% (1/19). Intraoperative AE
included intracranial or intratumoral hemorrhage from the
biopsy track [n= 2; Grade V (fatal) in one dog and clinical effects
unable to be evaluated in one dog], Grade I cerebrospinal fluid
(CSF) leakage from iatrogenic penetration of the lateral ventricle
with the biopsy needle (n= 1), and a Grade I break in aseptic
technique in the CT suite (n= 1). Aspiration of blood and CSF
from the biopsy needle accounted for the two biopsy attempts
in which brain tissue was unsuccessfully obtained. The case in
which lateral ventricular penetration occurred required that
the biopsy be performed using a second trajectory. The one
dog in which post-operative effects of FBSB-related intracranial
hemorrhage could not be evaluated was discharged from the
hospital 3 days after receiving the therapeutic intervention. The
case in which a break in aseptic technique occurred was treated
with a four-week course of cefovecin (8mg/kg SC q 14 days). No
adverse post-operative clinical effects were observed in either the
dog in which the lateral ventricle was penetrated or in the dog in
which there was a break in aseptic technique.
Post-operative AE included seizures in two dogs (Grade I,
n= 1 and Grade II, n= 1) and transient, Grade II exacerbation
of pre-existing neurological deficits (depression in consciousness,
hemiparesis, and circling) in one dog. Both dogs that experi-
enced post-operative seizures had been diagnosed with structural
epilepsy prior to the FBSB, were receiving anticonvulsant therapy
prior to biopsy, and received intravenous diazepam as a single or
intermittent bolus injection to treat post-operative seizures. The
dog that experienced a worsening of clinical signs of unilateral
forebrain signs was treated with mannitol (1.0 g/kg, IV) and pred-
nisone (1mg/kg/day PO), and returned to its baseline neurologi-
cal status 4 days after recovering from FBSB. No significant risk
factors associated with the development of adverse effects were
identified (Tables 5 and 6).
Aside from the changes anticipated from the FBSB procedure,
including the presence of craniectomy defects and small amounts
of gas or hemorrhage in the soft-tissues overlying the calvarium,
abnormalities were observed in immediate post-biopsy CT exam-
inations in 6/26 dogs. These included intracranial or intratumoral
hemorrhage (Figure 6) in two dogs, pneumocephalus contained
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TABLE 4 | Analysis of categorical risk factors associated with obtaining a non-diagnostic stereotactic brain biopsy.
Risk factor Category Number Non-diagnostic
biopsies
Diagnostic
biopsies
p Value
N (%) N (%)
Lesion side Left 12 1 (8:3) 11 (91:7) 1.00
Right 14 2 (14:3) 12 (85:7)
Lesion location Fronto-olfactory 3 0 (0:0) 3 (100:0) 0.91
Frontal 3 0 (0:0) 3 (100:0)
Frontoparietal 4 0 (0:0) 4 (100:0)
Piriform 4 1 (25:0) 3 (75:0)
Temporal-piriform 3 1 (33:3) 2 (66:7)
Temporal 3 1 (33:3) 2 (66:7)
Parieto-occipital 3 0 (0:0) 3 (100:0)
Parasellar 1 0 (0:0) 1 (100:0)
Thalamic 1 0 (0:0) 1 (100:0)
Hemispheric 1 0 (0:0) 1 (100:0)
WHO tumor grade I 1 0 (0:0) 1 (100:0) 1.00
II 9 1 (11:1) 8 (88:9)
III 8 1 (12:5) 7 (87:5)
IV 7 1 (14:3) 6 (85:7)
CT-guided biopsy No 12 1 (8:3) 11 (91:7) 1.00
Yes 14 2 (14:3) 12 (85:7)
CT, computed tomographic; WHO, World Health Organization.
TABLE 5 | Analysis of continuous risk factors for the development of
adverse events associated with stereotactic brain biopsy.
Risk
factor
Adverse events
present
Adverse events
absent
p Value
N Median
(range)
N Median
(range)
Surgeon experi-
ence (procedure
number)
7 15 (6–25) 12 18:5 (5–26) 0.59
Lesion volume (cm3) 7 2:5 (1:4–6:5) 12 1:7 (0:7–3:5) 0.17
Number biopsies
attempted
7 2 (1–4) 12 2 (1–4) 0.60
Needle error (mm) 4 1:6 (1:4–2:0) 4 1:8 (1:3–2:1) 0.78
Admission KPS 7 70 (50–90) 12 80 (40–90) 0.55
KPS, Karnofsky performance score.
within in the biopsy track in two dogs, ventricular pneumo-
cephalus in the dog in which the lateral ventricle was compro-
mised during the biopsy, and hypoattenuating mass effect in the
brain parenchyma surrounding the biopsy track, consistent with
edema, in the one dog that experienced transient clinical decline.
Discussion
The described stereotactic apparatus allowed for safe and effective
stereotactic brain biopsy. Based on our operational definition,
the overall diagnostic yield was 94.6%, which is similar to other
reports of FBSB in dogs and humans (3, 10, 14). Given the lack
of significant differences observed between patient demograph-
ics, lesion characteristics, number of intraoperative image-guided
procedures, proportion of non-diagnostic biopsies, and incidence
dogs of AE between the MRD and VTC headframes, we demon-
strate that both of these apparatus can be used successfully for
FBSB in dogs with focal forebrain masses both with and without
intraoperative image guidance. Although successful use of a free-
hand brain biopsy technique performed with MRI-imaging plan-
ning data translated to the operating theater has been described
in dogs with encephalitis, this is the first report describing the
clinical utility of FBSB performed without intraoperative image
guidance in dogs with spontaneous intracranial lesions (18).
Although no individual dog in this study was considered to
have a failed stereotactic biopsy procedure, defined as one in
which a definitive neuropathological diagnosis is not established
based on the tissue obtained, 5.4% (3/56) of individual biopsies
obtained in this study yielded non-specific changes that were not
representative of the primary underlying pathology (28). Sam-
pling of areas of necrosis, gliosis, or normal brain accounted for
the changes observed in non-diagnostic biopsy specimens. These
perilesional changes have also been shown to account for non-
representative biopsy of humans with high-grade gliomas (6, 28).
While the needle placement errors observed in this study were
within previously reported ranges for CT-guided FBSB in dogs,
needle placement errorwas significantly greater in non-diagnostic
biopsy specimens, emphasizing the need for accurate execution of
the planned trajectory when performing FBSB (9, 10, 20).
Calculation of the needle error is subject to inherent patient,
operator, and instrument inaccuracies associated with overall
error determinations, such as maintenance of rigid patient immo-
bilization throughout the procedure, correct coordinate registra-
tion to the frames, trajectory planning, needle insertions, and
coregistration of pre-operative and intraoperative image sets (19,
20). Additional technical factors, such as the amount of negative
pressure used to pull tissue samples into the biopsy window, were
neither controlled for nor quantified in this study, and could
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TABLE 6 | Analysis of potential risk factors for the development of adverse events associated with stereotactic brain biopsy.
Risk factor Category Number AE present
[N; (%)]
AE absent
[N; (%)]
p Value
Lesion side Left 9 4 (44:4) 5 (55:6) 0.65
Right 10 3 (30:0) 7 (70:0)
Lesion location Fronto-olfactory 2 1 (50:0) 1 (50:0) 0.74
Frontal 2 1 (50:0) 1 (50:0)
Frontoparietal 3 1 (33:3) 2 (66:7)
Piriform 2 0 (0:0) 2 (100:0)
Temporal-piriform 2 1 (50:0) 1 (50:0)
Temporal 3 0 (0:0) 3 (100:0)
Parieto-occipital 2 1 (50:0) 1 (50:0)
Parasellar 1 0 (0:0) 1 (100:0)
Thalamic 1 1 (100:0) 0 (0:0)
Hemispheric 1 1 (100:0) 0 (0:0)
Lesion type Astrocytoma 13 4 (30:8) 9 (69:2) 0.69
Oligodendroglioma 5 2 (40:0) 3 (60:0)
GME 1 1 (100:0) 0 (0:0)
WHO tumor grade I 1 0 (0:0) 1 (100:0) 0.06
II 7 2 (28:6) 5 (71:4)
III 5 4 (80:0) 1 (20:0)
IV 5 0 (0:0) 5 (100:0)
AE, adverse event; WHO, World Health Organization.
FIGURE 6 | Intracranial hemorrhage resulting from frame-based
stereotactic biopsy of a Grade III oligodendroglioma. Transverse, pre-
(A) and post-contrast (B) stereotactic planning CT scans demonstrating
hypoattenuating and non-enhancing mass lesion in the temporal region. On
the immediate post-biopsy, pre-contrast CT scan, biopsy-induced intracranial
hemorrhage is apparent as an ovoid, hyperattenuating lesion contained within
the dorsal and central aspect of the previously described hypoattenuating
mass (C). The craniectomy and implanted catheter guide pedestal (C)
through which the biopsy was performed are visible in the parietal bone dorsal
to the lesion. Initial diagnostic T2-weighted, transverse MR image (D),
illustrating the hyperintense lesion in the temporal lobe of this patient.
have also contributed to the generation of non-diagnostic biopsy
samples. The appropriate amount of negative pressure required to
obtain quality biopsy specimens is variable, and in our experience
can be influenced by the type of lesion sampled. For example, we
observed that the gelatinous matrix characteristic of many canine
oligodendrogliomas readily lends itself to the harvesting of robust
samples using side-cutting needles with application of slight neg-
ative pressure that are ideally suited for cytopathological prepara-
tions (31). However, the consistency of oligodendrogliomas also
presents challenges when attempting to preserve the integrity of
the tissue core during transfer from the biopsy needle. The size of
mass lesions subjected to biopsy could have also have contributed
favorably to our observed diagnostic yield. All masses in this
cohort of dogs were >4.5mm at their maximal two-dimensional
cross sectional diameter, which is a size reportedly amenable to
biopsy based on prior reports examining accuracies of frame-
based CT-guided biopsy (11, 16), and we found no significant
associations between lesion volume and the risk of non-diagnostic
biopsy. Although we were unable to identify a statistically sig-
nificant association between lesion volume and the risk of non-
diagnostic biopsy, it is clinically notable that the median volume
of masses yielding successful biopsies was greater than twice the
median volume of mass lesions from which non-diagnostic biop-
sies were obtained. Thus, the potential effects of lesion volume
on diagnostic yield may warrant further investigation in larger
numbers of dogs subjected to FBSB.
Studies have indicated that increasing the number of biopsies
harvested and usage of intraoperative histopathological examina-
tion of frozen sections and cytopathological evaluations increase
the diagnostic yield, and thus, reduce the likelihood of failed
stereotactic biopsy procedures (5, 31–33). While harvesting sev-
eral biopsy specimens deceases the risk for failed stereotactic
biopsy, some studies have indicated that increasing the number
of biopsies is also associated with an increasing risk for AE, espe-
cially when multiple biopsy trajectories are used (28, 34). In this
study, multiple biopsies were obtained using a single trajectory
whenever possible to potentially mitigate the development of AE,
but intraoperative AE required the use a second trajectory to
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obtain diagnostic tissue in one case. Although both intraoper-
ative cryosections and cytological preparations were performed
in selected cases reported here, they were neither used consis-
tently nor prepared or processed uniformly, and thus, we did not
evaluate their impact on diagnostic yield in this study.
Adverse events directly attributable to FBSB were observed in
7/26 (27%) of dogs, although the potential clinical sequelae of
the AE could be assessed in 19/26 dogs, which included 6/7 dogs
experiencing AE. Biopsy-associated clinical morbidity occurred
in 3/19 (16%) of dogs, and the case fatality rate was 5.2% (1/19
dogs). The morbidity and mortality rates observed in this study
are similar to previous investigations of FBSB investigations in
dogs with spontaneous intracranial disease, which have reported
case fatality rates of 7–8% and incidences of biopsy-associated
morbidity ranging from 12 to 27% (9, 13). Intracranial hemor-
rhage, exacerbation of seizures, and transient neurological deteri-
oration are recognized complications associated with brain biopsy
in dogs and humans, and accounted for all of the symptomatic AE
observed in this study (3, 10, 14, 18, 31).
Biopsy-induced hemorrhage is recognized as one of the most
common AE encountered during FBSB, and is also the AE most
often associated with procedural morbidity and mortality in both
dogs and humans (4–6, 10, 14, 31, 32). Similar to humans,
reports of canine stereotactic brain biopsies performed to date,
suggest that the majority of symptomatic intracranial biopsy-
related hemorrhages will declare themselves clinically in the acute
post-operative period (10, 14, 35, 36). As has been previously
demonstrated in humans and dogs, post-biopsy imaging exami-
nations were useful for the detection of procedural hemorrhage
and other complications, such as edema, and assisted with man-
agement of AE (10, 14, 35, 36). In humans undergoing stereotactic
brain biopsy, asymptomatic biopsy-related hemorrhage is com-
monly observed on post-operative imaging examinations, with an
approximate incidence of 50% (34–36). Delayed clinical deteri-
oration secondary to hemorrhage can occur up to several days
following biopsy in humans, and the risk for delayed hemorrhagic
AE is considered minimal in people with negative post-biopsy
imaging examinations that recover from the procedure without
incident (35, 36).
Both dogs in this case series that experienced post-operative
seizures had pre-existing tumor associated structural epilepsy and
were receiving anticonvulsant therapy at the time of enrollment.
In both of these cases, the provoked seizures were possible to
control with single or intermittent boluses of diazepam. However,
medically intractable seizures have been observed following FBSB
in dogs (10). Two intraoperative AE in this study, including iatro-
genic perforation of the lateral ventricle and a break in aseptic
technique in the CT suite, did not result in any clinically apparent
AE and resolved with no specific or minor specific interventions.
Asymptomatic ventricular pneumocephaluswas also reported in a
prior study investigating the clinical utility of minimally invasive,
free-hand brain biopsy in dogs with encephalitis (18).
Numerous risk factors associated with the development of
clinical morbidity have been identified in humans undergoing
FBSB. Some studies have independently recognized the histologic
diagnosis of highly vascularized, high-grade glioma as a risk factor
for morbidity, as well as the immune status of the patient, or
lesions that involve the basal ganglia or thalamus (4, 6, 34). Other
factors, such as patient age, pre-operative neurological status,
number of biopsy specimens taken, and target lesion size, have
been identified in some series and not others as factors associated
with post-operative morbidity andmortality (4, 34, 37). Although
we did not identify any significant risk factors associated with the
development of AE in this study, we commonly performed FBSB
in patientswith high-grade gliomas that often involved subcortical
basal nuclei. Our inability to detect risk factors may have been
affected by sample size limitations. The morbidity and mortality
rates observed here may also have been favorably influenced by a
patient population in which predominantly telencephalic lesions
were sampled, with only one dog undergoing FBSB for a thalamic
lesion. Stereotactic biopsy of brainstem lesions has been associated
with high mortality rates in dogs, although the specific locations
of biopsy targets within the brainstem were not always specified
in animals experiencing fatal complications (14).
Recognizing the inherent difficulties associated with presump-
tive diagnosis of intra-axialmass lesions-based exclusively on con-
temporaryMR sequences, as well as the inability ofMR imaging to
reliably distinguish between different types and grades of canine
gliomas, this study reinforces the importance of histopathological
diagnosis for the optimal management of patients with intracra-
nial disease (38, 39). In this cohort of dogs, one dog with a
presumptively diagnosed glioma based on imaging was ultimately
diagnosed with focal macrogranulomatous GME following FBSB,
which significantly and favorably altered this patient’s therapy and
prognosis.
Due to lack of universal access to necropsy or surgical
resection specimens, as well as the potential for some of the
therapies administered to alter the original phenotype of the
tumor, we made no attempt to evaluate the diagnostic accuracy of
FBSB (27). The diagnostic accuracy of FBSB can be defined as the
proportion of biopsies that generate diagnoses that are reflective
of the primary pathological process present in an individual
patient, and it is determined by comparison with “gold standard”
samples that are obtained following surgical resection of the
lesion or at necropsy.
An additional limitation of this study is the institutional selec-
tion bias inherent in the population of dogs subjected to FBSB.
With the exception of the single dog with the parasellar menin-
gioma, dogs were selected for FBSB based upon the presence of
an intra-axial forebrain mass lesion with imaging features com-
patible with a glioma for subsequent enrollment in investigative
clinical trials for the treatment of gliomas (38). However, one of
the most frequent indications for stereotactic biopsy in humans
is pathological diagnosis of deep-seated intra-axial masses, such
as gliomas (2, 4, 6). Thus, while our results with respect to the
diagnostic yield of FBSB and risks associated with non-diagnostic
biopsy and AE are relevant to dogs with focal gliomas involving
the forebrain, our conclusions are not applicable to the utility of
FBSB for lesions that are non-neoplastic, multifocal, or located
in the caudal brainstem. However, this report represents a large
cohort of dogs in which glial tumors were histopathologically
diagnosed antemortem, and indicates that FBSB can be used suc-
cessfully with acceptable clinical morbidity in dogs with forebrain
gliomas.
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Given the technique with which intraoperative image-guided
procedures were performed in this study, which required moving
the patient into and out of the operating theater and CT suite
twice, it is not unexpected that CT-guided FBSB procedural times
were significantly longer than those performed without intraop-
erative image guidance. Previous studies of CT-guided biopsies
in dogs describe performance of a minimally invasive burr-hole
approach in the radiology suite (10, 13, 14). However, we deviated
from these techniques because we often simultaneously instru-
mented the patient for a future therapeutic-intent procedure while
performing FBSB. These preparations required more extensive
surgical approaches and permanent implantation of electrode or
catheter guide pedestals into the skull (27).We believed that it was
indicated to perform these procedures in the aseptic environment
of the operating theater due to their anticipated length and inva-
siveness. No associations between procedural time and surgeon
experience were identified in this study, and the median dura-
tion of intraoperative image-guided biopsy was 138min. While
our intraoperative image-guided procedures took longer than the
60min required byMoissonnier to performCT-guided FBSB (14),
our procedural times were well within the ranges published in
another study in dogs, which reported durations of CT-guided
biopsy initially lasting 180–240min, but eventually being reduced
to 90–120min as the surgeon gained experience (9).
In conclusion, the two headframe systems utilized in this study
allowed for successful stereotactic biopsy of solitary, predomi-
nantly intra-axial forebrain masses both with and without intra-
operative CT-guidance. Among the 19 dogs in whichAE related to
FBSB could be evaluated, 84% (16/19) recovered without clinical
complications, including 2 dogs that experienced intraoperative
AE. Intracranial hemorrhage, seizures, and transient neurological
decline secondary to brain edema were the most common AE
observed in this study and accounted for all symptomaticAE.With
modifications to the micromanipulator arm, both headframes
described here could be used in MR-guided FBSB, which may
further improve the outcomes associated with stereotactic brain
biopsy in dogs.
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